Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
17. April 2024 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
02. April 2024 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, April 02, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
27. März 2024 08:30 ET
|
Adaptive Biotechnologies
SEATTLE, March 27, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
22. Februar 2024 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
14. Februar 2024 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
29. Januar 2024 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
27. Dezember 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
09. Dezember 2023 08:30 ET
|
Adaptive Biotechnologies
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD assessed from blood in multiple myeloma may be an indicator...
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
05. Dezember 2023 07:30 ET
|
Adaptive Biotechnologies
Data supporting clonoSEQ’s clinical and research utility, as well as insights based on analysis of real-world experience, will be featured at ASH.
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
09. November 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...